Jazz Pharmaceuticals (JAZZ) – Research Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for Jazz Pharmaceuticals (NASDAQ: JAZZ):

• 7/20/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $255.00 to $282.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Jazz Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $290.00 price target on the stock.
• 7/16/2026 – Jazz Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $265.00 to $285.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $253.00 to $260.00. They now have an “overweight” rating on the stock.
• 7/9/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Jazz Pharmaceuticals had its price target lowered by Truist Financial Corporation from $256.00 to $254.00. They now have a “buy” rating on the stock.
• 6/29/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “sell (d+)” to “hold (c-)”.
• 6/12/2026 – Jazz Pharmaceuticals was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.
• 6/10/2026 – Jazz Pharmaceuticals had its price target raised by Bank of America Corporation from $281.00 to $307.00. They now have a “buy” rating on the stock.
• 6/9/2026 – Jazz Pharmaceuticals had its “market perform” rating reaffirmed by Sanford C. Bernstein.
• 6/9/2026 – Jazz Pharmaceuticals was given a new $256.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.

Insider Transactions at Jazz Pharmaceuticals

In related news, Director Mark Douglas Smith sold 1,157 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the sale, the director directly owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This represents a 10.68% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the firm’s stock in a transaction that occurred on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the sale, the executive vice president owned 51,549 shares in the company, valued at approximately $11,950,604.67. The trade was a 2.27% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 13,098 shares of company stock valued at $3,131,906. Company insiders own 4.10% of the company’s stock.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.